ImmuneRegen BioSciences, Inc. Reports Scancell Collaboration Yielding Positive Results in Cancer Vaccine Studies of Homspera(R)

SCOTTSDALE, Ariz., Sept. 8, 2010 (GLOBE NEWSWIRE) -- ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB:IRBS), today announced that treatment with its lead compound, Homspera®, in combination with a DNA vaccine utilizing Scancell's ImmunoBody® technology significantly improved the immune response of the vaccine in an animal model. Follow-up studies are currently being performed to optimize the effects of Homspera in enhancing the next generation of Scancell's cancer vaccines.